Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Fosamprenavir Calcium Clear all

Conditions: HIV Infections
Interventions: Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Healthy Subjects
Interventions: fosamprenavir + ritonavir + methadone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Buffalo, New York

Conditions: Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease
Interventions: Fosamprenavir Calcium 700 MG Oral Tablet, Placebo; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Healthy
Interventions: Raltegravir, Fosamprenavir, Ritonavir; Drug
Lead sponsor: Garden State Infectious Disease Associates, PA; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, indinavir sulfate, tenofovir disoproxil fumarate, ritonavir, fosamprenavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 8 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: LEXIVA (GW433908), Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 10 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: PI, RTV, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more

Conditions: HIV Infection, Infection, Human Immunodeficiency Virus
Interventions: Half-boosted Fosamprenavir, Full Boosted Fosamprenavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more

Conditions: HIV Infection, Infection, Human Immunodeficiency Virus
Interventions: LEXIVA (GW433908), Ritonavir, KALETRA, EPIVIR, Ziagen, Abacavir/Lamivudine, Fosamprenavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 866 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more

Conditions: HIV Infections
Interventions: ATV/r, DRV/r; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 37
States / cities: Fountain Valley, California • Los Angeles, California • Sacramento, California + 31 more

Conditions: HIV Infection
Interventions: ritonavir, fosamprenavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 23
States / cities: Concord, California • Long Beach, California • Orlando, Florida + 15 more

Search by objective public record fields.

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.

Oral Fosamprenavir for GERD

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy